Overview: Fibrosis-4 Index Panel
Introduction: The Fibrosis-4 Index Panel is a diagnostic tool designed to assess liver fibrosis using serum samples. In India, FIB-4 (calculated from AST, ALT, platelet count, age) is a simple noninvasive score for advanced fibrosis in NAFLD, chronic hepatitis B/C, and alcoholic liver disease, with high negative predictive value for ruling out cirrhosis. High morbidity from underdiagnosis in rural/low-SES patients with silent NAFLD progression, limited FibroScan access, delayed lifestyle/antiviral therapy leading to decompensation. Per hepatology practices aligned with ICMR and Indian National Association for Study of the Liver guidelines, the test employs spectrophotometry for markers and FIB-4 calculation over 1-2 days with high accuracy, valuable for community screening and monitoring. This diagnostic falls under liver disease screening and targets patients with elevated ALT or NAFLD risk, addressing accurate fibrosis stratification to guide referral or intervention. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise noninvasive assessment and reducing cirrhosis burden. Its serum-based approach ensures reliable performance.
Other Names: FIB-4 Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: FIB-4 validated as low-cost surrogate; in India, adopted in hepatitis/NAFLD clinics.
Purpose: The test assesses 4 parameters including AST to calculate FIB-4 score, guide liver fibrosis evaluation, rule out advanced disease, inform management.
Test Parameters: 1. AST, 2. ALT, 3. Platelet Count, 4. FIB-4 Score.
Pretest Condition: Fasting 10-12 hours recommended; patients should report fatigue or risk factors.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on alcohol use, viral hepatitis, obesity, age.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated fibrosis including cirrhosis, benefits of noninvasive assessment, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and calculate FIB-4 within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or thrombocytopenia can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High FIB-4 indicates advanced fibrosis risk, necessitating specialist input. Low FIB-4 rules out cirrhosis.
Specialist Consultation: Hepatologists should be consulted for management.
Additional Supporting Tests: ELF, FibroScan for confirmation.
Test Limitations: Age/platelet dependent; comprehensive approach required.
References: Indian Journal of Gastroenterology 2024, Fibrosis Studies India 2023.
